Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). KPC Pharmaceuticals's share price for the quarter that ended in Mar. 2026 was ¥11.4. KPC Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 757 Mil. Therefore, KPC Pharmaceuticals's market cap for the quarter that ended in Mar. 2026 was ¥8,630 Mil.
KPC Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (¥10,567 Mil) to Dec. 2025 (¥9,508 Mil) and
declined
from Dec. 2025 (¥9,508 Mil) to Mar. 2026 (¥8,630 Mil).
KPC Pharmaceuticals's annual market cap
declined
from Dec. 2023 (¥15,812 Mil) to Dec. 2024 (¥11,998 Mil) and
declined
from Dec. 2024 (¥11,998 Mil) to Dec. 2025 (¥9,508 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. KPC Pharmaceuticals's Enterprise Value for Today is ¥7,827 Mil.
KPC Pharmaceuticals (SHSE:600422) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
KPC Pharmaceuticals Market Cap Related Terms
KPC Pharmaceuticals Market Cap Historical Data
* Premium members only.
The historical data trend for KPC Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KPC Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where KPC Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
KPC Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPC Pharmaceuticals (SHSE:600422) has a Market Cap of ¥6,260 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on KPC Pharmaceuticals and its competitors. According to the industry distribution chart, KPC Pharmaceuticals ranks #284 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is KPC Pharmaceuticals' Market Cap too high?
KPC Pharmaceuticals' current Market Cap is ¥6,260 Mil. Based on the distribution chart, KPC Pharmaceuticals ranks #284 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, KPC Pharmaceuticals ranks #284 out of 1022 companies for Market Cap. This puts KPC Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 221.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 221.60, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on KPC Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 221.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KPC Pharmaceuticals's current Market Cap is ¥6,260 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.84, compared to a current price of ¥8.27 — trading 30.2% below its estimated fair value. The current Market Cap is ¥6,260 Mil. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current Market Cap is ¥6,260 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?
Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥8.27 is trading 30.2% below its estimated GF Value™ of ¥11.84.
GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for SHSE:600422:
Market Cap: ¥6,260 Mil
GF Value™: ¥11.84 vs. price of ¥8.27 (30.2% below fair value)
No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
62GF Score
Get the complete analysis for SHSE:600422
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600422 has been successfully added to your 
